Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Everolimus by Novartis for Myelodysplastic Syndrome: Likelihood of Approval
Everolimus is under clinical development by Novartis and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase I...
Everolimus by Novartis for Ependymoma: Likelihood of Approval
Everolimus is under clinical development by Novartis and currently in Phase II for Ependymoma. According to GlobalData, Phase II drugs...
Everolimus by Novartis for Pediatric Diffuse Intrinsic Pontine Glioma: Likelihood of Approval
Everolimus is under clinical development by Novartis and currently in Phase I for Pediatric Diffuse Intrinsic Pontine Glioma. According to...
Everolimus by SoVarGen for Epilepsy: Likelihood of Approval
Everolimus is under clinical development by SoVarGen and currently in Phase I for Epilepsy. According to GlobalData, Phase I drugs...
Everolimus by Novartis for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
Everolimus is under clinical development by Novartis and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)....
Everolimus by Novartis for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
Everolimus is under clinical development by Novartis and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)....